Building upon the observed inverse correlation between NKp30 expression and IL-6 levels in NSCLC patients in vivo, as well as the in vitro evidence demonstrating IL-6-mediated suppression of NKp30 surface expression, this study elucidates a key mechanism underlying this impairment. Here, IL6 is linked to non-small cell lung carcinoma.